EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Myelopathy following intrathecal chemotherapy in a patient with acute lymphoblastic leukemia: a case report

Jiao Li, Xuehan Mao, Fan Yu, Yuehua Huang, Yanying Wang, Jingxian Li, Lihong Li, Bianhong Wang

Frontiers in Oncology · 29.07.2026 · 16

DOI: 10.3389/fonc.2026.1851172 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Frontiers in Oncology, online erschienen am 29.07.2026. Verfasst von Jiao Li und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua Medicine, Tsinghua University, Beijing, China. Die Arbeit nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Intrathecal chemotherapy is a standard treatment for central nervous system (CNS) involvement in acute lymphoblastic leukemia (ALL). However, it may lead to rare but severe neurotoxicity, including chemotherapy-induced myelopathy. We report a 58-year-old female with B-cell ALL who developed progressive myelopathy approximately one month after completing seven cycles of intrathecal chemotherapy for CNS relapse. She presented with bilateral lower limb weakness, sensory disturbance below the T4 level, and urinary retention. Spinal cord MRI showed T2-weighted hyperintense signals in the dorsal columns at C7–T2 without abnormal enhancement. Systemic inflammatory, autoimmune, infectious, metabolic, vascular, and leukemic infiltration etiologies were comprehensively excluded. The diagnosis of intrathecal chemotherapy-induced myelopathy was confirmed. Despite discontinuation of intrathecal chemotherapy and supportive treatment, neurological deficits remained partially irreversible at the 3-month follow-up. This case highlights that intrathecal chemotherapy-related myelopathy is a severe and potentially irreversible complication in patients with ALL undergoing CNS-directed therapy. Characteristic MRI findings and thorough differential diagnosis are essential for early recognition. Close neurological monitoring should be strengthened in neuro-oncological patients receiving intrathecal chemotherapy.

Schlagwörter

Stichwörter der Autor:innen

acute lymphoblastic leukemiacentral nervous system relapsedorsal columnintrathecal chemotherapymagnetic resonance imagingmyelopathyneuro-oncologyneurotoxicity

Autor:innen und Institutionen

  • Department of Hematology, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua Medicine, Tsinghua University, Beijing, China.

Zitieren

APA

Li, J., Mao, X., Yu, F., Huang, Y., Wang, Y., Li, J., Li, L., & Wang, B. (2026). Myelopathy following intrathecal chemotherapy in a patient with acute lymphoblastic leukemia: a case report. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1851172

Vancouver

Li J, Mao X, Yu F, Huang Y, Wang Y, Li J, et al. Myelopathy following intrathecal chemotherapy in a patient with acute lymphoblastic leukemia: a case report. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.1851172

BibTeX
@article{Li2026,
  author = {Li, Jiao and Mao, Xuehan and Yu, Fan and Huang, Yuehua and Wang, Yanying and Li, Jingxian and Li, Lihong and Wang, Bianhong},
  title = {Myelopathy following intrathecal chemotherapy in a patient with acute lymphoblastic leukemia: a case report},
  journal = {Frontiers in Oncology},
  year = {2026},
  volume = {16},
  doi = {10.3389/fonc.2026.1851172}
}
Kostenlos starten →